IDO1 and myeloid sarcoma: Evidence has been presented that IFN-β can activate both pathways of the kynurenine cascade in the plasma of MS patients, and that IFN-β also affects IDO-1 (though to a lesser extent), which in turn decreases QUIN production [42].